Wall Street analysts have been busy initiating coverage on several key players, providing valuable insights for investors. Let’s take a look at some of the top names that have caught their attention.
Arm Holdings plc (ARM):
Benchmark analyst Cody Acree kicked off coverage with a Hold rating. This comes after the company’s shares saw a 5.9% gain, closing at $147.37 on Friday. Arm Holdings, a leader in semiconductor technology, is a company to keep an eye on.Immunic, Inc. (IMUX):
EF Hutton’s Jason Kolbert initiated coverage with a Buy rating, setting a price target of $17. The news sent Immunic’s shares up 2%, closing at $1.52 on Friday. This biotech company is focused on developing therapies for autoimmune and inflammatory diseases, making it a potential investment opportunity.Biohaven Ltd. (BHVN):
Jefferies analyst Amy Li initiated coverage with a Buy rating, announcing a price target of $57. Biohaven’s shares responded with a 6.5% gain, closing at $38.08 on Friday. This pharmaceutical company is known for its focus on neurological and other chronic diseases, making it a promising prospect for investors.Yelp Inc. (YELP):
B of A Securities analyst Nitin Bansal took a more cautious approach, initiating coverage with an Underperform rating and setting a price target of $30. Despite this, Yelp’s shares saw a 2.2% gain, closing at $34.44 on Friday. This online review platform is a well-established company with a diverse customer base.Coya Therapeutics, Inc. (COYA):
HC Wainwright & Co. analyst Raghuram Selvaraju initiated coverage with a Buy rating and announced a price target of $18. Coya Therapeutics’ shares surged 7.4% to close at $6.40 on Friday. This biotech company is focused on developing therapies for neurodegenerative diseases, making it an interesting prospect for investors seeking long-term growth.These analyst ratings provide valuable insights into the potential of these companies, offering a starting point for investors seeking to make informed decisions. It’s important to note that these are just opinions and should be considered alongside other factors before making any investment choices.
